1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Xbrane Biopharma AB (publ)
  6. News
  7. Summary
    XBRANE   SE0007789409

XBRANE BIOPHARMA AB (PUBL)

(XBRANE)
  Report
Delayed Nasdaq Stockholm  -  05/20 11:29:41 am EDT
79.10 SEK   +0.89%
05/05Announcement from Xbrane Biopharma's annual general meeting
AQ
05/05TRANSCRIPT : Xbrane Biopharma AB, Q1 2022 Earnings Call, May 05, 2022
CI
05/05Xbrane Biopharma releases interim report for January – March 2022
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Xbrane Biopharma AB(OM:XBRANE) dropped from OMX Nordic Small Cap Index

01/04/2022 | 12:00am EDT

"Xbrane Biopharma AB (publ) has been removed from OMX Nordic Small Cap Index


ę S&P Capital IQ 2022
All news about XBRANE BIOPHARMA AB (PUBL)
05/05Announcement from Xbrane Biopharma's annual general meeting
AQ
05/05TRANSCRIPT : Xbrane Biopharma AB, Q1 2022 Earnings Call, May 05, 2022
CI
05/05Xbrane Biopharma releases interim report for January – March 2022
AQ
05/05Xbrane Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/02Invitation to presentation of Xbrane Biopharma's interim report January – March 2..
AQ
04/05Correction regarding notice of annual general meeting in Xbrane Biopharma
AQ
04/04Notice of annual general meeting in Xbrane Biopharma AB
AQ
03/31Xbrane Biopharma releases annual report 2021
AQ
03/09Xbrane Biopharma - Xciting and Increasingly Compelling Case
AQ
02/24TRANSCRIPT : Xbrane Biopharma AB, Q4 2021 Earnings Call, Feb 24, 2022
CI
More news
Financials
Sales 2021 18,7 M 1,88 M 1,88 M
Net income 2021 -225 M -22,6 M -22,6 M
Net cash 2021 445 M 44,7 M 44,7 M
P/E ratio 2021 -8,05x
Yield 2021 -
Capitalization 1 981 M 199 M 199 M
EV / Sales 2021 82,0x
EV / Sales 2022 5,75x
Nbr of Employees 64
Free-Float 66,3%
Chart XBRANE BIOPHARMA AB (PUBL)
Duration : Period :
Xbrane Biopharma AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends XBRANE BIOPHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 79,10 SEK
Average target price 235,00 SEK
Spread / Average Target 197%
EPS Revisions
Managers and Directors
Martin ┼mark Chief Executive Officer
Anette Lindqvist Chief Financial Officer & Head-Investor Relations
Anders Lennart Tullgren Chairman
David Vikstr÷m Chief Technology Officer
Siavash Bashiri Chief Operating Officer & Head-Biosimilars
Sector and Competitors
1st jan.Capi. (M$)
XBRANE BIOPHARMA AB (PUBL)-24.52%199
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567